Habil Khorakiwala on India's First FDA-Approved Antibiotic.
About this episode
Habil Khorakiwala discusses the journey of Wockhardt's FDA-approved antibiotic Zaynich and the strategic decisions behind its development.
Wockhardt's FDA approval of Zaynich marks a historic first, the only drug entirely discovered and developed by an Indian company to clear US-FDA scrutiny. ET’s pharma editor Vikas Dandekar and Rica Bhattacharyya talk to Habil Khorakiwala, Chairperson of Wockhardt who unpacks the 25-year innovation journey behind this milestone. From a deliberate pivot to antibiotics when big pharma was exiting the space, to navigating financial turbulence, asset sales, and regulatory hurdles, Khorakiwala reflects on strategic patience and scientific conviction. He also outlines peak sales projections of $1.5–2 billion, the US commercial roadmap led by daughter Zahabiya, and a robust pipeline of blockbusters ahead. You can follow Vikas Dandekar on his social media: X or Linkedin and Rica Bhattacharyya on her X and Linkedin Check out other interesting episodes like: ET Deep Dive: Swipe Left on Reality , India wants manufacturing at 25% of GDP — will AI in factories help? , Tanay Kothari Wants To Kill The Keyboard , From Doer to Director: The LinkedIn Playbook for the AI Agea , Semaglutide Goes Generic: Big Pharma’s Moat Breaks and much more . Catch the latest episode…
More episodes of The Morning Brief
- How Long Should You Stay in an SIP?
- RBI's Rupee Rx
- The Gold That Wasn't There: Inside SEBI's Case Against Rajesh Exports
- Zia Mody On Law, Legacy and Leadership
- ET Deep Dive: Lock, Stock and Worry
- Anthropic Goes Public: Can Markets Justify a $1 Trillion Value?
Explore listener stats, chart rankings, contacts and more on the The Morning Brief podcast page.